Biocartis Group NV (BIOGF)

0,6600 0,0000 (0,00%) Börsenschluss: 02:40PM EDT

Biocartis Group NV

Generaal de Wittelaan 11 B
Mechelen 2800
Belgium
32 1 563 26 00
https://www.biocartisgroupnv.be

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 526

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Piet Houwen	Chief Operating Officer	N/A	N/A	1968
Mr. Roger Moody	Chief Executive Officer	N/A	N/A	N/A
Mr. George A. Cardoza	CFO & Head of Service Delivery	N/A	N/A	1962
Mr. Benoit Devogelaere	Chief Technology Officer	N/A	N/A	1981
Mr. Geert Maertens Ph.D.	Chairman of Scientific Advisory Board & Chief Scientific Officer	N/A	N/A	N/A
Renate Degrave	Head of IR & Corporate Communications	N/A	N/A	N/A
Mr. Erik Vossenaar Ph.D.	Senior Vice-President of Corporate Development and Strategy	N/A	N/A	1973
Ms. Susy Spruyt	Head of People & Organization	N/A	N/A	1968
Dr. Erwin Sablon	Head of R&D and Alliance Management	N/A	N/A	1965
Mr. Reginald Van Genechten	Head of Manufacturing & Supply Chain	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2019 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Corporate Governance

Biocartis Group NVs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.